Notice to the Market – Launch of ZEVTERA in Argentina
NOTICE TO THE MARKET
Grupo Biotoscana announces launch of antibiotic Zevtera (ceftobiprole) in Argentina
Montevideo, Uruguay, March 6, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general, that it has launched Basilea’s broad spectrum hospital antibiotic ZEVTERA® (ceftobiprole) in Argentina.
In 2016, GBT and Basilea Pharmaceutica International Ltd. (SIX:BSLN) had entered into an exclusive agreement to commercialize two novel Basilea’s anti-infective agents: CRESEMBA® (isavuconazole) and ZEVTERA in Latin America. Under that agreement, GBT is responsible for marketing authorization, market access, promotion, selling and distribution in 19 countries in the region. The launch of ZEVTERA in Argentina, represents the first market introduction under that agreement.
Román Saglio, EVP Marketing GBT, said: “We are excited of making Zevtera’s commercially available in the first LATAM country and we continue working intensively to introduce both Zevtera and CRESEMBA into other countries within the region, upon regulatory approval”.
ZEVTERA was presented to the medical community last week, in an event organized along with the Argentinean Society of Infectious Disease (SADI), adjacent to the 18th International Congress of Infectious Disease held in Buenos Aires and attended by more than 400 specialists. During the meeting, results of a local study that assessed ceftobiprole’s antimicrobial activity against Gram-positive and Gram-negative microorganisms prevalent in Argentina were presented.
“Ceftobiprole is an advanced cephalosporin that offers broad bactericidal activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp and that has demonstrated to have excellent activity against local strains” said Dr. Daniel Flores, Sr. Scientific Advisor GBT.
Zevtera is approved in Argentina for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).
GBT – Grupo Biotoscana.
To access the PDF version, please click here.
Updated on 01/02/2019 at 04:39 pm